Business Context and Reporting Period
This Form 8-K is filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc.) on May 1, 2024. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "VIRI". The filing addresses a critical corporate governance issue regarding the continued listing of its securities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock listing standards rather than financial performance metrics.
Material Changes
- Listing Status: The company received a second notice from Nasdaq on May 1, 2024, confirming failure to meet the $1.00 minimum bid price requirement for the last 30 consecutive business days.
- Compliance Deadline: The initial 180-day compliance period expired on April 30, 2024.
- Delisting Stay: The company has requested a hearing with the Nasdaq Hearings Panel, which has stayed the delisting of its common stock pending the Panel's decision.
Outlook, Risks, and Management Commentary
Management intends to present a plan to the Nasdaq Hearings Panel to regain compliance. The proposed plan includes:
- Anticipated receipt of data from the study of IMC-2 for the treatment of Long-COVID conducted by the Bateman Horne Center.
- A commitment to effect a reverse stock split if necessary to meet the minimum bid price requirement.
Risks: The filing contains forward-looking statements regarding the Panel's decision and the company's ability to regain compliance. There is a substantial risk that the company may be delisted if the plan is not approved or if the stock price does not recover.
Investor Verification Checklist
- Verify the current status of the Nasdaq Hearings Panel decision regarding the delisting stay.
- Confirm the timeline and expected outcomes of the IMC-2 Long-COVID study data release.
- Monitor for any official announcements regarding the execution of a reverse stock split.
- Review the company's most recent Form 10-K/A for detailed financial liquidity and operational risks.